High expression of SLC2A1 inhibits ferroptosis and promotes proliferation and invasion of lung adenocarcinoma cells

doi:10.12122/j.issn.1673-4254.2024.12.17

Abstract

Abstract:

Objective To examine how the glucose transporter SLC2A1 influences the proliferation and migration of lung adenocarcinoma (LUAD) and explore the underlying molecular mechanisms. Methods We examined the differential expression of SLC2A1 between normal and LUAD tissues in the TCGA database and its prognostic implications. Immunohistochemistry was used to detect SLC2A1 protein levels in clinical samples of LUAD and adjacent tissues, and the association of SLC2A1 expression levels with clinicopathological features of the patients was analyzed. In PC9 cells with stable SLC2A1 overexpression or knockdown, the effects of SLC2A1 expression level on cell proliferation and migration were assessed using CCK-8 and Transwell assays, and the changes in expressions of ferroptosis- and autophagy-related proteins were measured; the occurrence of ferroptosis was confirmed using ROS and Fe²⁺ fluorescence staining. Results SLC2A1 expression was significantly higher in LUAD tumor tissues than in normal lung tissues (P<0.05) and was associated with worse pathological parameters and prognosis of the patients (P<0.05). In PC9 cells, SLC2A1 overexpression significantly promoted cell proliferation, invasion and migration, and SLC2A1 knockdown significanty increased cell death and inhibited cell invasion and proliferation. SLC2A1 knockdown caused obvious activation of cell ferroptosis, reduced GPX4 and xCT expressions, and increased intracellular levels of ROS and Fe²⁺. SLC2A1 knockdown also resulted in increased cell autophagy shown by increased LC3B expression, which could be reversed by treatement with 3-MA. Conclusion High SLC2A1 expression is correlated with poor prognosis of patients with LUAD, and inhibiting SLC2A1 can induce ferroptosis and autophagy of LUAD cells, suggesting the potential of SLC2A1 as a target for LUAD diagnosis and treatment.

Key words: lung adenocarcinoma, glucose transporter 1, ferroptosis, autophagy

Hong KUANG, Wenhan CAI, Yiming LIU, Jiaxin WEN, Shuo TIAN, Zhiqiang XUE. High expression of SLC2A1 inhibits ferroptosis and promotes proliferation and invasion of lung adenocarcinoma cells[J]. Journal of Southern Medical University, 2024, 44(12): 2404-2411.

Figures/Tables 9

Fig.1 Expression of SLC2A1 in lung adenocarcinoma (LUAD) and normal lung tissues and cells. A: Expression of SLC2A1 in LUAD and normal lung tissue. B: Expression of SLC2A1 in LUAD patients with different T grades. C: Expression of SLC2A1 in PC9 and BEAS-2B cell lines. *P<0.05, ****P<0.0001.

Tab.1 Relation between SLC2A1 and clinicopathological features of patients with LUAD (n)

Clinicopathological feature	n	SLC2A1 Low	SLC2A1 High	P
Gender				0.0577
Male	238	79	159
Female	278	112	166
Age (year)				<0.0001
<65	365	135	230
≥65	151	67	84
Tumor diameter (cm )				0.0351
<4	280	136	144
≥4	236	62	174
Fuhrman				0.2935
1-2	353	155	198
3-4	163	58	105

Fig.2 Diagnostic and prognostic values of SLC2A1 in LUAD. A: AUC curve feature of SLC2A1 in LUAD. B: Overall survival of LUAD patients with different levels of SLC2A1. C: Progression-free survival of LUAD patients with different levels of SLC2A1.

Tab.2 Univariate analysis of the correlations of SLC2A1 expression and clinicopathologic variables with overall survival of LUAD patients

Variable	n	Mean Survival (months)	P
Gender			0.2986
Male	156	69.2
Female	51	62.3
Age (year)			0.0620
<65	165	70.0
≥65	42	63.6
Tumor diameter ( cm )			0.0053
<4	71	71.2
≥4	136	67.0
Fuhrman			0.0270
1-2	153	71.7
3-4	54	60.1
SLC2A1 expression			0.0079
Low	59	71.7
High	148	69.2
T stage			0.1082
T1	52	71.0
T2	77	70.4
T3	78	65.5

Tab.3 COX multivariate analysis of clinicopathological parameters and overall survival of the patients

Variables	Hazard Ratio (95% CI)	P
Tumor diameter	1.239(1.136-1.352)	0.220
SLC2A1 expression	1.912(1.841-1.988)	0.024
Fuhrman	2.029(1.995-2.063)	0.194

Fig.3 Expression of SLC2A1 protein in LUAD and normal lung tissues. ****P<0.0001.

Fig.4 Knockdown of SLC2A1 inhibits proliferation and migration of LUAD cells. A: Efficiency of SLC2A1 knockdown in PC9 cells. B: qRT-PCR data showing SLC2A1 mRNA expression in PC9 with or without shRNA. C: CCK-8 assay for assessing proliferation of PC9 cells with SLC2A1 downregulation. D: Migration ability of PC9 cells with SLC2A1 downregulation. E: Invasion ability of PC9 cells with SLC2A1 downregulation. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig.5 Overexpression of SLC2A1 promotes proliferation and migration of LUAD cells.A: Efficiency of SLC2A1 overexpression in PC9 cells. B: qRT-PCR of SLC2A1 mRNA expression in PC9 cells with or without SLC2A1 overexpression. C: CCK-8 for assessing proliferation of PC9 cells overexpressing SLC2A1. D: Migration ability of PC9 cells overexpressing SLC2A1. E: Invasion of PC9 cells overexpressing SLC2A1. Scar bar=100 μm. **P<0.01, ***P<0.001, ****P<0.0001 vs control group.

Fig.6 SLC2A1 knockdown promotes autophagy and iron death in PC9 cells. A: Western blotting of ferroptosis-related proteins in PC9 cells with SLC2A1 knockdown. B: Intracellular Fe2+ level in PC9 cells with SLC2A1 knockdown. C: Mito-Fe2+ level in PC9 cells with SLC2A1 knockdown. D: Intracellular ROS level in PC9 cells with SLC2A1 knockdown. E: Knockdown of SLC2A1 induces autophagy in PC9 cells. F: 3-MA resuced SLC2A1 knockdown-induced autophagy of PC9 cells. G: Knockdown of SLC2A1 induces cell death in PC9 cells. Scar bar=100 μm. **P<0.01, ***P<0.001, ****P<0.0001.

References 26

1	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(1): 7-33.
2	Lin WL, Chen Y, Wu BM, et al. Identification of the pyroptosis-related prognostic gene signature and the associated regulation axis in lung adenocarcinoma[J]. Cell Death Discov, 2021, 7(1): 161.
3	Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations[J]. J Clin Oncol, 2022, 40(6): 611-25.
4	Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family[J]. Annu Rev Nutr, 1996, 16: 235-56.
5	Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma[J]. Cancer, 2003, 97(4): 1015-24.
6	Amann T, Maegdefrau U, Hartmann A, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis[J]. Am J Pathol, 2009, 174(4): 1544-52.
7	Wachi S, Yoneda K, Wu RE. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues[J]. Bioinformatics, 2005, 21(23): 4205-8.
8	Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers[J]. Pathol Oncol Res, 2012, 18(3): 721-8.
9	Dixon SJ. Ferroptosis: bug or feature?[J]. Immunol Rev, 2017, 277(1): 150-7.
10	Chen X, Kang R, Kroemer G, et al. Ferroptosis in infection, inflammation, and immunity [J]. J Exp Med, 2021, 218(6): 223-35.
11	Jiang XJ, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-82.
12	Liu XS, Yang JW, Zeng J, et al. SLC2A1 is a diagnostic biomarker involved in immune infiltration of colorectal cancer and associated with m6A modification and ceRNA[J]. Front Cell Dev Biol, 2022, 10: 853596.
13	Relli V, Trerotola M, Guerra E, et al. Abandoning the notion of non-small cell lung cancer[J]. Trends Mol Med, 2019, 25(7): 585-94.
14	Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157: 103194.
15	Yao J, Tang SM, Shi CY, et al. Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma[J]. Autophagy, 2023, 19(4): 1221-38.
16	Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion[J]. Nat Rev Cancer, 2019, 19(7): 405-14.
17	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death [J]. Cell, 2012, 149(5): 1060-72.
18	Larraufie MH, Yang WS, Jiang E, et al. Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility[J]. Bioorg Med Chem Lett, 2015, 25(21): 4787-92.
19	Ou WJ, Mulik RS, Anwar A, et al. Low-density lipoprotein docosa-hexaenoic acid nanoparticles induce ferroptotic cell death in hepato-cellular carcinoma[J]. Free Radic Biol Med, 2017, 112: 597-607.
20	Yuan H, Li XM, Zhang XY, et al. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation[J]. Biochem Biophys Res Commun, 2016, 478(2): 838-44.
21	Bai T, Wang S, Zhao YP, et al. Haloperidol, a Sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2017, 491(4): 919-25.
22	Hao SH, Yu J, He WM, et al. Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells[J]. Neoplasia, 2017, 19(12): 1022-32.
23	Galadari S, Rahman A, Pallichankandy S, et al. Reactive oxygen species and cancer paradox: To promote or to suppress [J]. Free Radic Biol Med, 2017, 104: 144-64.
24	Sun XF, Niu XH, Chen RC, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology, 2016, 64(2): 488-500.
25	Zheng DW, Lei Q, Zhu JY, et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy[J]. Nano Lett, 2017, 17(1): 284-91.
26	Zhu S, Zhang QH, Sun XF, et al. HSPA5 regulates ferroptotic cell death in cancer cells[J]. Cancer Res, 2017, 77(8): 2064-77.

[1]	Kai CHEN, Zhaofei MENG, Jingting MIN, Jiahui WANG, Zhenghong LI, Qin GAO, Junfeng HU. Curcumin alleviates septic lung injury in mice by inhibiting TXNIP/TRX-1/GPX4-mediated ferroptosis [J]. Journal of Southern Medical University, 2024, 44(9): 1805-1813.
[2]	Mingzi OUYANG, Jiaqi CUI, Hui WANG, Zheng LIANG, Dajin PI, Liguo CHEN, Qianjun CHEN, Yingchao WU. Kaixinsan alleviates adriamycin-induced depression-like behaviors in mice by reducing ferroptosis in the prefrontal cortex [J]. Journal of Southern Medical University, 2024, 44(8): 1441-1449.
[3]	Mingyang ZHU, Bokang WANG, Xiusen ZHANG, Kexu ZHOU, Zeyu MIAO, Jiangtao SUN. Assessment of baseline CCL19⁺ dendritic cell infiltration for predicting responses to immunotherapy in lung adenocarcinoma patients [J]. Journal of Southern Medical University, 2024, 44(8): 1529-1536.
[4]	Yinliang ZHANG, Zetan LUO, Rui ZHAO, Na ZHAO, Zhidong XU, Di AO, Guyi CONG, Xinyu LIU, Hailun ZHENG. Sanguinarine induces ferroptosis of colorectal cancer cells by upregulating STUB1 and downregulating GPX4 [J]. Journal of Southern Medical University, 2024, 44(8): 1537-1544.
[5]	Yao CHENG, Yuanying WANG, Feiyang YAO, Pan HU, Mingxian CHEN, Ning WU. Baicalin suppresses type 2 dengue virus-induced autophagy of human umbilical vein endothelial cells by inhibiting the PI3K/AKT pathway [J]. Journal of Southern Medical University, 2024, 44(7): 1272-1283.
[6]	Yeming ZHANG, Yuanxiang ZHANG, Xuebin SHEN, Guodong WANG, Lei ZHU. MiRNA-103-3p promotes neural cell autophagy by activating Wnt/β-catenin signaling via targeting rab10 in a rat model of depression [J]. Journal of Southern Medical University, 2024, 44(7): 1315-1326.
[7]	Qianyi CHEN, Shuhan SHANG, Huan LU, Sisi LI, Zhimian SUN, Xirui FAN, Zhilin QI. Calenduloside E inhibits hepatocellular carcinoma cell proliferation and migration by down-regulating GPX4 and SLC7A11 expression through the autophagy pathway [J]. Journal of Southern Medical University, 2024, 44(7): 1327-1335.
[8]	Yuanguo WANG, Peng ZHANG. Ferroptosis suppressor genes are highly expressed in esophageal cancer to inhibit tumor cell ferroptosis [J]. Journal of Southern Medical University, 2024, 44(7): 1389-1396.
[9]	Huaxing HE, Lulin LIU, Yingyin LIU, Nachuan CHEN, Suxia SUN. Sodium butyrate and sorafenib synergistically inhibit hepatocellular carcinoma cells possibly by inducing ferroptosis through inhibiting YAP [J]. Journal of Southern Medical University, 2024, 44(7): 1425-1430.
[10]	Zhixian REN, Beixian ZHOU, Linxin WANG, Jing LI, Rongping ZHANG, Xiping PAN. Inhibitory effect of 5-hydroxy-6,7-dimethoxyflavone on H1N1 influenza virus-induced ferroptosis and inflammation in A549 cells and its possible mechanisms [J]. Journal of Southern Medical University, 2024, 44(6): 1070-1078.
[11]	Fangyuan ZHANG, Gang LIU. Dexmedetomidine inhibits ferroptosis of human renal tubular epithelial cells by activating the Nrf2/HO-1/GPX4 pathway [J]. Journal of Southern Medical University, 2024, 44(6): 1135-1140.
[12]	Nan WANG, Bin SHI, Xiaolan MAN, Weichao WU, Jia CAO. High expression of fragile X mental retardation protein inhibits ferroptosis of colorectal tumor cells by activating the RAS/MAPK signaling pathway [J]. Journal of Southern Medical University, 2024, 44(5): 885-893.
[13]	Leilei SHEN, Ying CHEN, Tianyang YUN, Juntang GUO, Xi LIU, Tao ZHANG, Chaoyang LIANG, Yang LIU. Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases [J]. Journal of Southern Medical University, 2024, 44(5): 989-997.
[14]	ZHOU Fengmin, GUO Yanju, CHEN Ning. Exercise promotes irisin expression to ameliorate renal injury in type 2 diabetic rats [J]. Journal of Southern Medical University, 2024, 44(4): 675-681.
[15]	CHEN Junjie, HUANG Chuanbing, LI Ming. Jianpi Zishen granule inhibits podocyte autophagy in systemic lupus erythematosus: a network pharmacology and clinical study [J]. Journal of Southern Medical University, 2024, 44(3): 465-473.